$GEVA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in SYNAGEVA BIOPHARMA CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in SYNAGEVA BIOPHARMA CORP. Get notifications about new insider transactions in SYNAGEVA BIOPHARMA CORP for free.
Page: < prev 1 2 3 4 5 6 ... 9 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Buy | M | 40.32 | 833 | 33,587 | 1,301 | 468 to 1.3 K (+177.99 %) |
| Apr 29 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 1.70 | 10,000 | 17,000 | 37,228 | |
| Apr 29 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 110.00 | 10,000 | 1,100,000 | 5,637 | 15.6 K to 5.6 K (-63.95 %) |
| Apr 29 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 1.70 | 10,000 | 17,000 | 15,637 | 5.6 K to 15.6 K (+177.40 %) |
| Apr 23 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 108.00 | 10,000 | 1,080,000 | 5,637 | 15.6 K to 5.6 K (-63.95 %) |
| Apr 17 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 40.74 | 10,000 | 407,400 | 35,000 | |
| Apr 17 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 105.00 | 10,000 | 1,050,000 | 15,637 | 25.6 K to 15.6 K (-39.01 %) |
| Apr 17 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 40.74 | 10,000 | 407,400 | 25,637 | 15.6 K to 25.6 K (+63.95 %) |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Option Exercise | M | 57.56 | 24,600 | 1,415,976 | 15,000 | |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Option Exercise | M | 40.32 | 15,263 | 615,404 | 21,668 | |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Option Exercise | M | 40.32 | 2,769 | 111,646 | 36,931 | |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Sell | S | 96.08 | 39,863 | 3,830,037 | 468 | 40.3 K to 468 (-98.84 %) |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Buy | M | 57.56 | 24,600 | 1,415,976 | 40,331 | 15.7 K to 40.3 K (+156.38 %) |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Buy | M | 40.32 | 15,263 | 615,404 | 15,731 | 468 to 15.7 K (+3,261.32 %) |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Sell | S | 96.04 | 2,769 | 265,935 | 468 | 3.2 K to 468 (-85.54 %) |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Buy | M | 40.32 | 2,769 | 111,646 | 3,237 | 468 to 3.2 K (+591.67 %) |
| Apr 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Grant | A | 76.88 | 85 | 6,535 | 468 | 383 to 468 (+22.19 %) |
| Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 23.00 | 9,503 | 218,569 | 20,497 | |
| Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 0.95 | 10,000 | 9,500 | 8,964 | |
| Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 93.76 | 29,503 | 2,766,201 | 15,637 | 45.1 K to 15.6 K (-65.36 %) |
| Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 23.00 | 9,503 | 218,569 | 45,140 | 35.6 K to 45.1 K (+26.67 %) |
| Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 0.95 | 10,000 | 9,500 | 35,637 | 25.6 K to 35.6 K (+39.01 %) |
| Apr 08 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Grant | A | 76.88 | 42 | 3,229 | 25,637 | 25.6 K to 25.6 K (+0.16 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Option Exercise | M | 40.74 | 7,500 | 305,550 | 7,500 | |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 105.74 | 300 | 31,722 | 390 | 690 to 390 (-43.48 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 104.57 | 1,510 | 157,901 | 690 | 2.2 K to 690 (-68.64 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 103.55 | 3,290 | 340,680 | 2,200 | 5.5 K to 2.2 K (-59.93 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 102.46 | 900 | 92,214 | 5,490 | 6.4 K to 5.5 K (-14.08 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 101.38 | 600 | 60,828 | 6,390 | 7 K to 6.4 K (-8.58 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Sell | S | 100.44 | 900 | 90,396 | 6,990 | 7.9 K to 7 K (-11.41 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Buy | M | 40.74 | 7,500 | 305,550 | 7,890 | 390 to 7.9 K (+1,923.08 %) |
| Mar 13 2015 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | SVP, Finance and Bu ... | Grant | A | 76.88 | 86 | 6,612 | 390 | 304 to 390 (+28.29 %) |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 40.74 | 29,062 | 1,183,986 | 15,938 | |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 1.70 | 13,235 | 22,500 | 9,929 | |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 101.69 | 1,842 | 187,313 | 0 | 1.8 K to 0 (-100.00 %) |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 100.74 | 16,716 | 1,683,970 | 1,842 | 18.6 K to 1.8 K (-90.07 %) |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 99.97 | 14,750 | 1,474,558 | 18,558 | 33.3 K to 18.6 K (-44.28 %) |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 98.85 | 8,989 | 888,563 | 33,308 | 42.3 K to 33.3 K (-21.25 %) |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 40.74 | 29,062 | 1,183,986 | 42,297 | 13.2 K to 42.3 K (+219.58 %) |
| Feb 19 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 1.70 | 13,235 | 22,500 | 13,235 | 0 to 13.2 K |
| Jan 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | P | 94.19 | 1,000,000 | 94,190,000 | 9,184,771 | 8.2 M to 9.2 M (+12.22 %) |
| Jan 09 2015 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER JULIAN | Director | Buy | P | 94.19 | 1,000,000 | 94,190,000 | 9,184,771 | 8.2 M to 9.2 M (+12.22 %) |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Option Exercise | M | 23.00 | 5,000 | 115,000 | 5,000 | |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Option Exercise | M | 1.70 | 1,100 | 1,870 | 838 | |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Sell | S | 93.04 | 300 | 27,912 | 304 | 604 to 304 (-49.67 %) |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Sell | S | 92.10 | 1,156 | 106,468 | 604 | 1.8 K to 604 (-65.68 %) |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Sell | S | 91.34 | 2,844 | 259,771 | 1,760 | 4.6 K to 1.8 K (-61.77 %) |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Sell | S | 89.90 | 1,800 | 161,820 | 4,604 | 6.4 K to 4.6 K (-28.11 %) |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Buy | M | 23.00 | 5,000 | 115,000 | 6,404 | 1.4 K to 6.4 K (+356.13 %) |
| Dec 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Buy | M | 1.70 | 1,100 | 1,870 | 1,404 | 304 to 1.4 K (+361.84 %) |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | M | 23.00 | 31,448 | 723,304 | 136,052 | |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | M | 3.52 | 5,016 | 17,656 | 0 | |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | M | 1.70 | 13,536 | 23,011 | 22,512 | |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 90.06 | 26,960 | 2,428,018 | 1,031 | 28 K to 1 K (-96.32 %) |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 87.26 | 4,488 | 391,623 | 27,991 | 32.5 K to 28 K (-13.82 %) |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 87.55 | 13,536 | 1,185,077 | 32,479 | 46 K to 32.5 K (-29.42 %) |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Sell | S | 87.25 | 5,016 | 437,646 | 46,015 | 51 K to 46 K (-9.83 %) |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Buy | M | 23.00 | 31,448 | 723,304 | 51,031 | 19.6 K to 51 K (+160.59 %) |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Buy | M | 3.52 | 5,016 | 17,656 | 19,583 | 14.6 K to 19.6 K (+34.43 %) |
| Dec 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Buy | M | 1.70 | 13,536 | 23,011 | 14,567 | 1 K to 14.6 K (+1,312.90 %) |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 23.00 | 7,854 | 180,642 | 7,292 | |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 1.70 | 15,050 | 25,585 | 23,164 | |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 23.00 | 1,000 | 23,000 | 15,146 | |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 1.70 | 1,500 | 2,550 | 38,214 | |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 80.11 | 22,904 | 1,834,839 | 0 | 22.9 K to 0 (-100.00 %) |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 23.00 | 7,854 | 180,642 | 22,904 | 15.1 K to 22.9 K (+52.19 %) |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 1.70 | 15,050 | 25,585 | 15,050 | 0 to 15.1 K |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 80.00 | 1,000 | 80,000 | 0 | 1,000 to 0 (-100.00 %) |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 80.00 | 1,500 | 120,000 | 1,000 | 2.5 K to 1,000 (-60.00 %) |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 23.00 | 1,000 | 23,000 | 2,500 | 1.5 K to 2.5 K (+66.67 %) |
| Oct 30 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 1.70 | 1,500 | 2,550 | 1,500 | 0 to 1.5 K |
| Sep 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Bazemore Robert B | Chief Operating Off ... | Option Exercise | A | 63.11 | 50,000 | 3,155,500 | 50,000 | |
| Sep 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Bazemore Robert B | Chief Operating Off ... | Grant | A | 0.00 | 30,000 | 0 | 30,000 | 0 to 30 K |
| Sep 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Option Exercise | M | 8.73 | 790 | 6,897 | 34,697 | |
| Sep 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Sell | S | 65.24 | 790 | 51,540 | 562 | 1.4 K to 562 (-58.43 %) |
| Sep 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Buy | M | 8.73 | 790 | 6,897 | 1,352 | 562 to 1.4 K (+140.57 %) |
| Sep 18 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Option Exercise | M | 8.73 | 4,200 | 36,666 | 35,487 | |
| Sep 18 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Option Exercise | M | 8.73 | 9,379 | 81,879 | 39,687 | |
| Sep 18 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Sell | S | 65.06 | 4,200 | 273,252 | 562 | 4.8 K to 562 (-88.20 %) |
| Sep 18 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Buy | M | 8.73 | 4,200 | 36,666 | 4,762 | 562 to 4.8 K (+747.33 %) |
| Sep 18 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Sell | S | 65.01 | 9,379 | 609,729 | 562 | 9.9 K to 562 (-94.35 %) |
| Sep 18 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Buy | M | 8.73 | 9,379 | 81,879 | 9,941 | 562 to 9.9 K (+1,668.86 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | M | 23.00 | 10,000 | 230,000 | 30,000 | |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 72.88 | 300 | 21,864 | 25,595 | 25.9 K to 25.6 K (-1.16 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 71.96 | 700 | 50,372 | 25,895 | 26.6 K to 25.9 K (-2.63 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 70.50 | 400 | 28,200 | 26,595 | 27 K to 26.6 K (-1.48 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Sell | S | 69.88 | 8,600 | 600,968 | 26,995 | 35.6 K to 27 K (-24.16 %) |
| Sep 04 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Buy | M | 23.00 | 10,000 | 230,000 | 35,595 | 25.6 K to 35.6 K (+39.07 %) |
| Jul 02 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Grant | A | 54.89 | 71 | 3,897 | 25,595 | 25.5 K to 25.6 K (+0.28 %) |
| Jul 02 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Grant | A | 54.89 | 112 | 6,148 | 304 | 192 to 304 (+58.33 %) |
| Jul 02 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Grant | A | 54.89 | 103 | 5,654 | 562 | 459 to 562 (+22.44 %) |
| Jul 02 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Grant | A | 54.89 | 117 | 6,422 | 383 | 266 to 383 (+43.98 %) |
| Jun 26 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Option Exercise | M | 57.56 | 400 | 23,024 | 39,600 | |
| Jun 26 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Option Exercise | M | 40.32 | 300 | 12,096 | 39,700 | |
| Jun 26 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Sell | S | 108.02 | 700 | 75,614 | 266 | 966 to 266 (-72.46 %) |
| Jun 26 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Buy | M | 57.56 | 400 | 23,024 | 966 | 566 to 966 (+70.67 %) |
| Jun 26 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Buy | M | 40.32 | 300 | 12,096 | 566 | 266 to 566 (+112.78 %) |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Option Exercise | M | 25.00 | 1,375 | 34,375 | 0 | ||
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Sell | S | 100.00 | 1,375 | 137,500 | 0 | 1.4 K to 0 (-100.00 %) | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Buy | M | 25.00 | 1,375 | 34,375 | 1,375 | 0 to 1.4 K | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 60.45 | 4,250 | 256,913 | 0 | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 60.45 | 4,250 | 256,913 | 0 | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 60.45 | 4,250 | 256,913 | 0 | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 60.45 | 4,250 | 256,913 | 0 | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 60.45 | 4,250 | 256,913 | 0 | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 60.45 | 4,250 | 256,913 | 0 | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 60.45 | 4,250 | 256,913 | 0 | |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 60.45 | 4,250 | 256,913 | 223,864 | 219.6 K to 223.9 K (+1.94 %) |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 60.45 | 4,250 | 256,913 | 8,184,771 | 8.2 M to 8.2 M (+0.05 %) |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 60.45 | 4,250 | 256,913 | 112,740 | 108.5 K to 112.7 K (+3.92 %) |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 60.45 | 4,250 | 256,913 | 1,748,315 | 1.7 M to 1.7 M (+0.24 %) |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 60.45 | 4,250 | 256,913 | 67,729 | 63.5 K to 67.7 K (+6.70 %) |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 60.45 | 4,250 | 256,913 | 177,463 | 173.2 K to 177.5 K (+2.45 %) |
| Jun 24 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Buy | M | 60.45 | 4,250 | 256,913 | 219,050 | 214.8 K to 219.1 K (+1.98 %) |
| Jun 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Option Exercise | M | 23.95 | 1,000 | 23,950 | 1,000 | ||
| Jun 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Sell | S | 90.00 | 1,000 | 90,000 | 0 | 1,000 to 0 (-100.00 %) | |
| Jun 19 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Buy | M | 23.95 | 1,000 | 23,950 | 1,000 | 0 to 1,000 | |
| Jun 16 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Option Exercise | M | 23.00 | 1,000 | 23,000 | 8,375 | ||
| Jun 16 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Sell | S | 83.31 | 1,000 | 83,310 | 0 | 1,000 to 0 (-100.00 %) | |
| Jun 16 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Buy | M | 23.00 | 1,000 | 23,000 | 1,000 | 0 to 1,000 | |
| Jun 12 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Option Exercise | M | 8.73 | 18,637 | 162,701 | 49,066 | |
| Jun 12 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Option Exercise | M | 0.95 | 1,034 | 982 | 0 | |
| Jun 12 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Option Exercise | M | 0.95 | 1,926 | 1,830 | 0 | |
| Jun 12 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Sell | S | 80.00 | 21,597 | 1,727,760 | 459 | 22.1 K to 459 (-97.92 %) |
| Jun 12 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Buy | M | 0.95 | 1,034 | 982 | 22,056 | 21 K to 22.1 K (+4.92 %) |
| Jun 12 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Buy | M | 8.73 | 18,637 | 162,701 | 21,022 | 2.4 K to 21 K (+781.43 %) |
| Jun 12 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Buy | M | 0.95 | 1,926 | 1,830 | 2,385 | 459 to 2.4 K (+419.61 %) |
| Jun 06 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | A | 80.35 | 15,000 | 1,205,250 | 15,000 | |
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quinn Anthony | EVP, CMO & Head of ... | Option Exercise | A | 80.35 | 45,000 | 3,615,750 | 45,000 | |
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Quart Barry D | Option Exercise | A | 80.35 | 7,500 | 602,625 | 7,500 | ||
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | WIRTH PETER | Option Exercise | A | 80.35 | 7,500 | 602,625 | 7,500 | ||
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Williams Glen | SVP, Technical Oper ... | Option Exercise | A | 80.35 | 45,000 | 3,615,750 | 45,000 | |
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Patel Sanj K | President & CEO | Option Exercise | A | 80.35 | 120,000 | 9,642,000 | 120,000 | |
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | TISCH THOMAS J | Option Exercise | A | 80.35 | 7,500 | 602,625 | 7,500 | ||
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Malley Thomas | Option Exercise | A | 80.35 | 7,500 | 602,625 | 7,500 | ||
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Heberlig Chris | Group Vice Presiden ... | Option Exercise | A | 80.35 | 12,000 | 964,200 | 12,000 | |
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | Goldberg Mark Alan | EVP, Medical & Reg. ... | Option Exercise | A | 80.35 | 30,000 | 2,410,500 | 30,000 | |
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | DAVIS STEPHEN | Option Exercise | A | 80.35 | 7,500 | 602,625 | 7,500 | ||
| Jun 05 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | A | 80.35 | 40,000 | 3,214,000 | 40,000 | |
| May 20 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Option Exercise | M | 1.70 | 9,927 | 16,876 | 39,714 | |
| May 20 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 83.46 | 200 | 16,692 | 0 | 200 to 0 (-100.00 %) |
| May 20 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 82.71 | 1,591 | 131,592 | 200 | 1.8 K to 200 (-88.83 %) |
| May 20 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Sell | S | 81.75 | 8,136 | 665,118 | 1,791 | 9.9 K to 1.8 K (-81.96 %) |
| May 20 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BOESS CARSTEN | SVP, Chief Financia ... | Buy | M | 1.70 | 9,927 | 16,876 | 9,927 | 0 to 9.9 K |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 | |
| Apr 25 2014 | GEVA | SYNAGEVA BIOPHARMA ... | BAKER FELIX | Director | Option Exercise | M | 65.10 | 8,000 | 520,800 | 0 |